|Day's Range||225.75 - 225.75|
|52 Week Range||225.75 - 246.55|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AstraZeneca and Clovis could challenge Tesaro's PARP inhibitor ovarian cancer treatment, Leerink says.
For 2016, AstraZeneca (AZN) reported revenues of about $5.8 billion for its emerging markets business, which is a YoY (year-over-year) rise of about 6.0%.
For 2016, Synagis reported 2% growth at constant exchange rates, following its 14% growth in sales in the US.